

SUTHERLAND

999 Peachtree St., N.E.
Atlanta, GA 30309-3696
404.853.8000 Fax 404.853.6606
www.sutherland.com

ATLANTA
AUSTIN
HOUSTON
NEW YORK
WASHINGTON DC

Facsimile**CONFIDENTIAL****Date:** February 3, 2010**Pages (including cover):** 2**TO:**Recipient NameFirm/CompanyFaxTelephone

Examiner Lynn Bristol

U.S. Patent & Trademark Office

571.273.6883

571.272.6883

FROM: WILLIAM L. WARREN **Email address:** bill.warren@sutherland.com
Telephone: 404.853.8081 **User number:** 1295 **Client number:** 20825-0004
Message:

Re: U.S. Application No. 10/799,417
Applicant: Paul A. Krieg
Title: "METHODS FOR MODULATING ANGIOGENESIS WITH APELIN COMPOSITIONS"
Our Ref. No.: 20825-0004

Dear Examiner Bristol:

Pursuant to our telephone interview on February 2, 2010 to discuss the enablement issue; enclosed please find a proposed set of claims to overcome the objections.

Regards,



William L. Warren
Reg. No. 36,714

This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination or distribution of this communication to other than the intended recipient is strictly prohibited. If you have received this communication in error, please notify us immediately by online telephone at 404.853.8813 and return the original message to us at the above address via the U.S. Postal Service. Thank you.

8903529.1

U.S. Utility Patent Application Serial No. 10/799,417 entitled,
"METHODS FOR MODULATING ANGIOGENESIS WITH APELIN COMPOSITIONS"

PROPOSED AMENDMENTS FOR DISCUSSION – DO NOT ENTER

1. (Currently Amended) A method of inhibiting angiogenesis in a biological sample, comprising
 - a. providing a biological sample; and
 - b. combining the biological sample in vivo with an angiogenesis-inhibiting amount of a composition comprising ~~an inhibitor of apelin activity~~ an anti-apelin antibody or fragment thereof that binds the apelin polypeptide of SEQ ID NO:4 and inhibits angiogenesis, wherein the angiogenesis is characterized by in vivo generation of a new blood vessel from an existing blood vessel.
2. (Original) The method of Claim 1, wherein the composition decreases vascular permeability in the biological sample.
3. (Currently Amended) The method of Claim 1, wherein the composition interferes with the interaction of ~~an the~~ apelin polypeptide or apelin peptide with a receptor polypeptide.
4. (Currently Amended) The method of Claim 1, wherein the composition interferes with the interaction of ~~an the~~ apelin polypeptide or apelin peptide with APJ.

5-20 (Canceled)

21. (Original) The method of Claim 1, wherein the composition comprises a pharmaceutically acceptable carrier.
22. (Previously Presented) The method of Claim 1, wherein the biological sample is a mammalian biological sample.
23. (Original) The method of Claim 1, wherein the biological sample is a human biological sample.
24. (Original) The method of Claim 23, wherein the biological sample is in a patient.

25-59. (Canceled)